- Alpha Cognition Inc. launches ZUNVEYL in the U.S. market, targeting long-term care facilities.
- First quarter 2025 revenues include $347,000 from ZUNVEYL sales and $2.6 million from a CMS Pharma partnership.
- The company holds cash and equivalents totaling $45.5 million, with a projected cash runway of two years.
Alpha Cognition Inc. (ACOG, Financial), a commercial-stage biopharmaceutical company, has reported its financial outcomes for the first quarter of 2025, ending March 31. The highlight of the quarter was the successful launch of ZUNVEYL®, a benzgalantamine-based drug, in the U.S. market specifically targeting long-term care facilities. CEO Michael McFadden noted positive clinician feedback regarding ZUNVEYL's impact on cognitive functions and its strong initial demand reflected in wholesale orders and product replenishments.
The company revealed net product revenues of $347,000 from ZUNVEYL sales and $2.6 million in licensing revenue from a partnership with CMS Pharma. Research and development expenses declined to $408,000 from $917,000 in the same quarter of the previous year. Meanwhile, selling, general, and administrative expenses increased to $5.4 million, primarily due to commercial-readiness activities, compared to $3.5 million in the first quarter of 2024. Alpha Cognition narrowed its net loss to $2.0 million from $5.0 million in the same period the previous year.
Alpha Cognition's financial stability is supported by cash and cash equivalents of $45.5 million as of March 31, 2025, down from $48.6 million at the end of 2024. At its current cash utilization rate, the company anticipates a two-year cash runway, positioning it well for future growth and expansion activities. Additionally, the company strengthened its intellectual property portfolio with a new patent covering the tablet formulation of benzgalantamine, securing protection in the U.S. through 2044 and globally through 2041.
